7 results match your criteria second-generation btki

  • Page 1 of 1

The Use of Bruton's Tyrosine Kinase Inhibitors to Treat Allergic Disorders.

Curr Treat Options Allergy 2021 Apr 16:1-13. Epub 2021 Apr 16.

Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD USA.

Purpose Of Review: Studies show that inhibitors of Bruton's tyrosine kinase (BTKis), currently FDA-approved for the treatment of B cell malignancies, can prevent IgE-mediated reactions through broad inhibition of the FcεRI signaling pathway in human mast cells and basophils. This review will summarize recent data supporting the use of these drugs as novel therapies in various allergic disorders.

Recent Findings: Recent studies have shown that BTKis can prevent IgE-mediated degranulation and cytokine production in primary human mast cells and basophils. Read More

View Article and Full-Text PDF

Managing toxicities of Bruton tyrosine kinase inhibitors.

Hematology Am Soc Hematol Educ Program 2020 12;2020(1):336-345

Columbia University Medical Center, New York, NY.

Inhibition of Bruton's tyrosine kinase (BTK) has revolutionized the treatment landscape for patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal B-cell receptor signaling, BTK inhibitors (BTKis) impair cell proliferation, migration, and activation of NF-κB. Clinically, because indefinite inhibition is a mainstay of therapy, there is an extended period of exposure in which adverse effects can develop. Read More

View Article and Full-Text PDF
December 2020

Emerging drugs for the treatment of Waldenström macroglobulinemia.

Expert Opin Emerg Drugs 2020 12 21;25(4):433-444. Epub 2020 Sep 21.

Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens , Athens, Greece.

Introduction: Waldenström's Macroglobulinemia (WM) is an indolent lymphoma with uniquely distinct and heterogenous clinical and genomic profiles. Clonal lymphoplasmacytic cells secrete monoclonal IgM. More than 90% of patients harbor a mutation in MYD88 gene, leading to the constitutive activation of downstream pathways, involving BTK-mediated signaling. Read More

View Article and Full-Text PDF
December 2020

The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.

Expert Rev Anticancer Ther 2020 08 13;20(8):663-674. Epub 2020 Jul 13.

Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens , Athens, Greece.

Introduction: Waldenstrom's Macroglobulinemia (WM) is a rare, indolent lymphoplasmacytic lymphoma characterized by heterogeneous clinical and genomic profile. Bruton's tyrosine kinase (BTK) is central to the signaling pathways required for clonal WM cell survival, and BTK inhibitors currently have an imperative role in the treatment of WM.

Areas Covered: The central role of BTK in WM will be described, and the rationale behind the development of BTKi. Read More

View Article and Full-Text PDF

Bruton Tyrosine Kinase Inhibitors: Present and Future.

Jan A Burger

Cancer J 2019 Nov/Dec;25(6):386-393

From the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that plays a central role in the signal transduction of the B-cell antigen receptor and other cell surface receptors, both in normal and malignant B lymphocytes. B-cell antigen receptor signaling is activated in secondary lymphatic organs and drives the proliferation of malignant B cells, including chronic lymphocytic leukemia (CLL) cells. During the last 10 years, BTK inhibitors (BTKis) are increasingly replacing chemotherapy-based regimen, especially in patients with CLL and mantle cell lymphoma (MCL). Read More

View Article and Full-Text PDF

Targeting BTK in CLL: Beyond Ibrutinib.

Curr Hematol Malig Rep 2019 06;14(3):197-205

Department of Internal Medicine, Division of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, 445D Wiseman Hall CCC, 410 W 12th Ave, Columbus, OH, 43210, USA.

Purpose Of Review: While the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL), current limitations include off-target toxicities and the development of resistance. In this review, we summarize the emerging data for alternative BTKi.

Recent Findings: Second-generation BTKi include acalabrutinib, zanubrutinib, and tirabrutinib which offer greater BTK selectivity. Read More

View Article and Full-Text PDF

Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.

Leuk Lymphoma 2018 07 13;59(7):1554-1564. Epub 2017 Sep 13.

a Department of Haematology , St Vincent's Hospital Melbourne , Fitzroy , Australia.

The development of bruton tyrosine kinase inhibitors (BTKi) has been a significant advancement in the treatment of chronic lymphocytic leukemia and related B-cell malignancies. As experience in using ibrutinib increased, the first drug to be licensed in its class, atrial fibrillation (AF) emerged as an important side effect. The intersection between BTKi therapy for B-cell malignancies and AF represents a complex area of management with scant evidence for guidance. Read More

View Article and Full-Text PDF
  • Page 1 of 1